We Don't Need More Reasons to Reject Heritable Genome Modification
By Katie Hasson,
The Hill
| 06. 10. 2019
Late last year, scientist He Jiankui announced the birth of the world’s first genetically modified babies. He deployed a technology known as CRISPR to alter the genomes of two embryos that he used to initiate a pregnancy; their mother carried the pregnancy until the two girls, publicly called Lulu and Nana, were delivered prematurely by C-section.
The response of scientists, bioethicists, and the public was immediate and overwhelmingly negative. He’s reckless actions violated Chinese regulations, crossed a bright line that dozens of countries have written into their laws, flouted nearly every rule of medical ethics, and exposed two girls to grave and unknowable risks.
This week, a study emerged highlighting the dangers of what He did, especially based on our current level of understanding. He attempted to disable a gene called CCR5 by producing a variant that has been shown to confer resistance to HIV. But the new study suggests that having non-working copies of CCR5 actually has an overall negative effect on health, specifically a 21 percent increase in mortality before age 76.
These findings...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Diaa Hadid and Shweta Desai, NPR | 01.29.2026
MUMBRA, India — The afternoon sun shines on the woman in a commuter-town café, highlighting her almond-shaped eyes and pale skin, a look often sought after by couples who need an egg to have a baby.
"I have good eggs,"...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...